Technical Analysis for OPTN - OptiNose, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| MACD Bearish Signal Line Cross | Bearish | 0.00% | |
| Doji - Bullish? | Reversal | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Gapped Down | Weakness | 0.00% | |
| Down 3 Days in a Row | Weakness | -2.03% | |
| Fell Below 20 DMA | Bearish | -3.91% | |
| Stochastic Sell Signal | Bearish | -9.87% | |
| NR7 | Range Contraction | -9.87% | |
| Inside Day | Range Contraction | -9.87% |
| Alert | Time |
|---|---|
| Down 5% | about 17 hours ago |
| Down 3% | about 17 hours ago |
| Down 2 % | about 17 hours ago |
| New 52 Week Low | about 17 hours ago |
| 60 Minute Opening Range Breakdown | about 17 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/07/2024
OptiNose, Inc. is a pharmaceutical company. The Company is focused on the development and commercialization of products for patients treated by ear, nose and throat, or ENT, and allergy specialists. The Company’s products candidates include XHANCE (Nasal Polyps), XHANCE (Chornic Sinusitis) OPN-300, OPN-021, and other. The Company’s lead product, XHANCE (fluticasone propionate) nasal spray, utilizes breath powered exhalation delivery system (EDS), to deliver a topically acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. XHANCE has a differentiated clinical profile with the potential to become part of the standard of care for this disease because it is able to deliver medication to the primary site of inflammation
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Medicine Clinical Medicine Pharmaceutical Disease Organ Systems Inflammation Allergy Respiratory Therapy Polyp Sinus Glucocorticoids Chronic Rhinosinusitis Corticosteroid Sinusitis Fluticasone Nasal Polyps Nasal Spray
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Medicine Clinical Medicine Pharmaceutical Disease Organ Systems Inflammation Allergy Respiratory Therapy Polyp Sinus Glucocorticoids Chronic Rhinosinusitis Corticosteroid Sinusitis Fluticasone Nasal Polyps Nasal Spray
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 2.1 |
| 52 Week Low | 0.65 |
| Average Volume | 350,448 |
| 200-Day Moving Average | 1.13 |
| 50-Day Moving Average | 0.81 |
| 20-Day Moving Average | 0.73 |
| 10-Day Moving Average | 0.75 |
| Average True Range | 0.05 |
| RSI (14) | 37.50 |
| ADX | 20.51 |
| +DI | 14.39 |
| -DI | 22.90 |
| Chandelier Exit (Long, 3 ATRs) | 0.66 |
| Chandelier Exit (Short, 3 ATRs) | 0.80 |
| Upper Bollinger Bands | 0.82 |
| Lower Bollinger Band | 0.64 |
| Percent B (%b) | 0.2 |
| BandWidth | 25.17 |
| MACD Line | -0.02 |
| MACD Signal Line | -0.02 |
| MACD Histogram | -0.002 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.79 | ||||
| Resistance 3 (R3) | 0.79 | 0.76 | 0.77 | ||
| Resistance 2 (R2) | 0.76 | 0.73 | 0.75 | 0.76 | |
| Resistance 1 (R1) | 0.72 | 0.71 | 0.70 | 0.71 | 0.76 |
| Pivot Point | 0.68 | 0.68 | 0.67 | 0.68 | 0.68 |
| Support 1 (S1) | 0.64 | 0.66 | 0.63 | 0.64 | 0.60 |
| Support 2 (S2) | 0.61 | 0.64 | 0.61 | 0.59 | |
| Support 3 (S3) | 0.57 | 0.61 | 0.58 | ||
| Support 4 (S4) | 0.57 |
